Uses:-Management of manifestations of psychotic disorders-Treatment of schizophrenia One of the most concerning side effects of Compazine is the development of a muscle disorder known as Tardive dyskinesia,   which can occur after long-term Compazine may also affect the pressure in the eye, and people who have glaucoma should always tell their physician before taking Compazine.

compazine-spansules-prochlorperazine-342055 PO: Immediate-release, 5-10 mg q6-8hr; extended-release, 10 mg q12hr or 15 mg every morningIV: 2.5-10 mg q3-4hr; not to exceed 10 mg/dose or 40 mg/dayIM: 5-10 mg administered 1-2 hours before induction of anesthesia; may be repeated once 30 minutes after initial doseIV: 5-10 mg administered 15-30 minutes before induction of anesthesia, repeated once before procedure if desired, or 20 mg/L administered 15-30 minutes before induction; not to exceed 30 mg/day5-10 mg PO q6-8hr; slowly titrate dose q2-3days; not to exceed 150 mg/day10-20 mg IM q2-4hr to gain control; 3-4 doses rarely needed2-6 years: 2.5 mg PO/PR q8-12hr initially; not to exceed 20 mg/day; not to exceed 10 mg on the first day6-12 years: 2.5 mg PO/PR q8-12hr initially; not to exceed 25 mg/day; not to exceed 10 mg on the first day≥2 years (9-13 kg): 2.5 mg PO daily or q12hr; not to exceed 7.5 mg/day ≥2 years (13.1-18 kg): 2.5 mg PO q8-12hr; not to exceed 10 mg/day≥2 years (18.1-37 kg): 2.5 mg PO q8hr or 5 mg PO q12hr; not to exceed 15 mg/dayNot drug of choice in elderly, because of extrapyramidal symptomsLower initial dose and adjust gradually; 2.5-5 mg/day PO; dosing interval may be increased to q8-12hr PRN; not to exceed 75 mg/dayRestlessness (immediate restlessness or agitation may be treated with diphenhydramine 25 mg IV push)Extrapyramidal symptoms (muscle stiffness, dystonia, parkinsonism, tardive dyskinesia)Neuroleptic malignant syndrome (infrequent but serious)Patients with dementia-related psychosis who are treated with antipsychotic drugs are at an increased risk of death, as shown in short-term controlled trials; the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in natureThis drug is not approved for treatment of patients with dementia-related psychosisComa, severe CNS depression, concurrent use of large amounts of CNS depressants, poorly controlled seizure disorder, subcortical brain damagePostoperative management of nausea/vomiting following pediatric surgeryAvoid using in children with suspected Reye syndromeUse caution in evere hypertension, severe cardiovascular diseaseUse with caution in glaucoma, prostatic hypertrophy, stenosing peptic ulcer disease, history of neuroleptic malignant syndrome, Parkinson disease, hypocalcemia, renal/hepatic impairment, history of severe reactions to insulin or electroconvulsive therapy, history of seizures, asthma, respiratory tract infections, cardiovascular disease, myelosuppressionBlood dyscrasias including neutropenia, agranulocytosis, and leukopenia reported with use; discontinue therapy at first sign of blood dyscrasiasRisk of extrapyramidal symptoms, neuroleptic malignant syndrome, hypotension (may be particularly severe in patients with pheochromocytoma or mitral insufficiency)Esophageal dysmotility/aspiration may occur; use with caution in patients at risk of pneumoniaDepresses hypothalamic thermoregulatory mechanism; exposure to extreme temperatures may cause hypo- or hyperthermiaMay alter cardiac conduction; life-threatening arrhythmias reported with therapeutic dosesMay cause anticholinergic effects (constipation, xerostomia, urinary retention, blurred vision); use caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, visual problemsMay cause pigmentary retinopathy and lenticular and corneal deposits, especially in prolonged therapyMay cause sedation and impair ability to perform tasks which require mental alertness, including operating heavy machineryIn case of severe hypotension, use norepinephrine or phenylepinephrine; do not use epinephrine or dopamineAntiemetic effect may obscure toxicity of chemotherapeutic drugsUse may be associated with neuroleptic malignant syndrome; monitor muscle rigidity, mental status changes, fever, autonomic instabilityMay need anticholinergic antiparkinsonian agent to counter extrapyramidal symptomsFDA warning regarding off-label use for dementia in elderlyLactation: Phenothiazines may be excreted in breast milk; do not nurseA: Generally acceptable.